FDA Picks Eli Lilly, Regeneron for Fast-Track Manufacturing Review
The FDA has selected seven companies, including Eli Lilly and Regeneron, for its new PreCheck Pilot Program to accelerate manufacturing facility reviews.
The U.S. Food and Drug Administration has chosen Eli Lilly and Regeneron as two of the first seven participants in its newly launched PreCheck Pilot Program, a regulatory initiative designed to streamline and accelerate the review of new pharmaceutical manufacturing facilities, according to reporting by CNBC.
The program signals a meaningful shift in how the agency approaches manufacturing oversight — a process that has historically been a bottleneck in getting new drugs and therapies to market. By front-loading facility inspections and compliance checks earlier in the review cycle, the PreCheck model aims to reduce the lag time between a drug winning approval and its manufacturer being cleared to produce it at scale.
Read more Tilray Brands Acquires HelloMD to Build Integrated Medical Cannabis Network →
For companies like Eli Lilly, which is racing to expand production capacity for its blockbuster weight-loss and diabetes drugs, and Regeneron, known for its biologics pipeline, participation in the pilot could translate into a tangible competitive advantage. Faster manufacturing clearances mean shorter timelines from regulatory approval to commercial supply — a critical factor in high-demand therapeutic categories where supply constraints have drawn significant public and political scrutiny.
The selection of just seven companies for the pilot's initial cohort suggests the FDA is proceeding cautiously, likely using this phase to benchmark the program's effectiveness before considering a broader rollout. How the agency measures success — whether by inspection cycle times, compliance rates, or time-to-market metrics — will shape whether PreCheck becomes a standard feature of drug manufacturing regulation or remains a limited-access tool.
The initiative reflects broader pressure on the FDA to modernize its operational infrastructure at a moment when domestic pharmaceutical manufacturing has become a matter of both economic and national security policy. Continue reading at US Top News and Analysis.
